ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

ClinicalTrials.gov ID: NCT01964924

Public ClinicalTrials.gov record NCT01964924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer

Study identification

NCT ID
NCT01964924
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
37 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 1, 2013
Primary completion
Jan 19, 2017
Completion
Apr 22, 2018
Last update posted
Sep 19, 2019

2013 – 2018

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
MedStar Georgetown University Hospital Washington D.C. District of Columbia 20007
Moffitt Cancer Center Tampa Florida 33612
Roswell Park Cancer Institute Buffalo New York 14263
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599
Case Western Reserve University Cleveland Ohio 44106
Cleveland Clinic Foundation Cleveland Ohio 44195
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Virginia Commonwealth University/Massey Cancer Center Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01964924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 19, 2019 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01964924 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →